Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina

被引:2
|
作者
Garay, Osvaldo Ulises [1 ]
Guinazu, Gonzalo [2 ]
Patricia Adamczuk, Yolanda [3 ]
Duboscq, Cristina [4 ]
机构
[1] Roche Diagnost Int Ltd, Rotkreuz, Switzerland
[2] Roche Diagnost Argentina, Rawson 3150 B1610BAL Ricardo Rojas, Buenos Aires, DF, Argentina
[3] Hosp Gen Agudos Dr Enrique Tornu, Buenos Aires, DF, Argentina
[4] Hosp Britan Buenos Aires, Buenos Aires, DF, Argentina
关键词
ORAL ANTICOAGULATION; ATRIAL-FIBRILLATION; MANAGEMENT; GUIDELINES; WARFARIN; THERAPY; STROKE;
D O I
10.1007/s41669-022-00352-4
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Worldwide, 1 % of the population receives anticoagulation therapy, with prevalence higher in older adults. Difficulties in the adequate management of these patients have led to the development of strategies focused on achieving therapeutic control and reducing adverse events with efficient use of resources. Objective To estimate the cost utility and budget impact on the Argentinean health system of implementation of anticoagulation clinics (ACs) (with and without use of point-of-care [POC] CoaguChek((R)) devices [Roche Diagnostics International Ltd]) compared with the traditional laboratory method (non-AC settings) for the management of anticoagulated patients. Methods For the cost-utility analysis, a cohort-based state transition model was designed to compare costs and health outcomes of implementing ACs for outpatient management of anticoagulated patients. The budget impact analysis used an analytical model to estimate the differential costs of implementing an AC and the expected adverse events avoided, and the differential costs of an international normalized ratio (INR) determination using a POC device rather than a conventional laboratory. Results We calculated the study outcomes for a cohort of 1000 patients. Considering a 5 % discount rate, the use of ACs generated 13.9 additional quality-adjusted life-years (0.014 per patient) and 12.5 additional life-years (0.013 per patient). Incremental cost-effectiveness ratios of AC implementation with and without the use of POC devices compared with the scenario without ACs were dominant in both cases. In the probabilistic sensitivity analysis, nearly all simulated results were cost effective (i.e., below the 1 or 3 gross domestic product per capita thresholds). Budget impact analysis results showed AC implementation generated savings from the first year of implementation, with savings of AR $265,325 by year 5. The addition of POC devices in the ACs also generated savings as early as the first year of implementation, with savings of AR $488,072 by year 5 (AR $488 per patient). Conclusions Anticoagulation clinics are estimated to be cost effective and generate notable savings in the treatment of patients on long-term oral anticoagulant therapy when compared with non-AC settings. These savings are considerably higher when POC devices are added as part of the patient management, due to lower laboratory technician costs per INR determination.
引用
收藏
页码:657 / 668
页数:12
相关论文
共 50 条
  • [1] Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina
    Osvaldo Ulises Garay
    Gonzalo Guiñazú
    Yolanda Patricia Adamczuk
    Cristina Duboscq
    PharmacoEconomics - Open, 2022, 6 : 657 - 668
  • [2] COST-UTILITY AND BUDGET IMPACT ANALYSIS OF IMPLEMENTING ANTICOAGULATION CLINICS AND POINT-OF-CARE MONITORING DEVICES IN ANTICOAGULATED PATIENTS IN ARGENTINA
    Garay, O. U.
    Guinazu, G.
    Adamczuk, Y.
    Duboscq, C.
    VALUE IN HEALTH, 2022, 25 (07) : S360 - S360
  • [3] Is point-of-care accurate for indicating thrombolysis in anticoagulated patients on oral anticoagulation treatments?
    Bruch, Tatiana P.
    Mendes, Danielle C.
    Pedrozo, Jeff C.
    Figueiredo, Livia
    Novak, Edison M.
    Zetola, Viviane F.
    Lange, Marcos C.
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2014, 72 (07) : 487 - 489
  • [4] POINT-OF-CARE INR MONITORING DEVICES FOR PATIENTS ON LONG-TERM ORAL ANTICOAGULATION THERAPY
    Khan, T.
    VALUE IN HEALTH, 2009, 12 (03) : A142 - A142
  • [5] The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care
    Kip, Michelle M. A.
    Koffijberg, Hendrik
    Moesker, Marco J.
    IJzerman, Maarten J.
    Kusters, Ron
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [6] The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care
    Michelle M. A. Kip
    Hendrik Koffijberg
    Marco J. Moesker
    Maarten J. IJzerman
    Ron Kusters
    BMC Cardiovascular Disorders, 17
  • [7] A budget impact model and a cost-utility analysis of reducer device (Neovasc) in patients with refractory angina
    Fortunato, Agostino
    Valentini, Ilaria
    Rumi, Filippo
    Antonini, Debora
    Siviero, Ludovica
    Di Brino, Eugenio
    Basile, Michele
    Cicchetti, Americo
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [8] Budget impact and cost-utility analysis of universal infant rotavirus vaccination in Spain
    Imaz, Inaki
    Rubio, Beltran
    Cornejo, Ana M.
    Gonzalez-Enriquez, Jesus
    PREVENTIVE MEDICINE, 2014, 61 : 116 - 121
  • [9] Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis
    Chen, Lei
    Chen, Xianqiu
    Zhi, Canghong
    Li, Xuan
    Hu, Yang
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 966 - 973
  • [10] US Cost-effectiveness and Budget Impact of Point-of-Care NAAT for Streptococcus
    Bilir, S. Pinar
    Kruger, Eliza
    Faller, Mathilde
    Munakata, Julie
    Karichu, James K.
    Sickler, Joanna
    Cheng, Mindy M.
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (05): : E157 - +